Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Conatus Pharmaceuticals
company
About
Conatus Pharmaceuticals is focused on the development of human therapeutics to treat liver failures and cancer.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $20M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2005
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to date its development has been the primary focus of the Company.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$20M
Conatus Pharmaceuticals has raised a total of
$20M
in funding over 2 rounds. Their latest funding was raised on
Feb 11, 2011 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 11, 2011 | Series B | $20M | 1 |
AgeChem Venture Fund
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Conatus Pharmaceuticals is funded by 1 investors.
AgeChem Venture Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
AgeChem Venture Fund
|
Yes | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
